γδ T cells modulate anti-tumor immunity in small cell lung cancer.
It is demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate can sensitize SCLC cells to γδ T cell-mediated killing.